SCHEMBL3528656

SCHEMBL3528656

Cn1c(COc2ccc(F)cc2)c(C2CC2)c(=O)n1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
NOX4 Q9NPH5 1/20 0.40
HTR7 P34969 1/20 0.39
HTR1A P08908 1/20 0.39
DRD2 P14416 1/20 0.39
HTR2A P28223 1/20 0.39
HRH1 P35367 1/20 0.39
DRD3 P35462 1/20 0.39
TMEM97 Q5BJF2 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
MAPK1 P28482 1/20 0.38
MAPT P10636 2/20 0.38
RAB9A P51151 2/20 0.37
FPR2 P25090 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALOX5 P09917 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3530750 0.94 MCHR1 (0.38) NOX4MAPTRAB9AALDH1A1SMN1; SMN2
SCHEMBL3531357 0.87 NOX4 (0.43) HSD11B1MEN1KMT2ANOX4HTR1A
SCHEMBL3529685 0.84 HTR1A (0.41) MEN1KMT2AHTR1ADRD2HTR2A
SCHEMBL3531667 0.81 HSD11B1 (0.38) HSD11B1MEN1KMT2ARAB9AALDH1A1
SCHEMBL3531070 0.79 MEN1 (0.53) MEN1KMT2ANOX4MAPTALDH1A1
SCHEMBL3528063 0.77 HSD11B1 (0.38) HSD11B1MEN1KMT2AHTR7FPR2
SCHEMBL3526739 0.76 HSD11B1 (0.46) HSD11B1MEN1KMT2AMAPTALDH1A1
SCHEMBL3532268 0.75 CCR3 (0.41) HSD11B1MEN1KMT2AHTR7HTR2A
SCHEMBL3530986 0.71 MEN1 (0.47) HSD11B1MEN1KMT2AHTR7FPR2
SCHEMBL3527433 0.71 HSD11B1 (0.41) HSD11B1MEN1KMT2AHTR7MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652057-B2 Pyrazolones as 11b-HSD1 inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2010-01-26 US claimed
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 US claimed
US-7652057-B2 Pyrazolones as 11b-HSD1 inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2010-01-26 US disclosed
EP-1924562-A2 PYRAZOLONE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-05-28 EP disclosed
WO-2007025880-A2 PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-03-08 WO disclosed
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes HSD11B1, HSD17B1, HSD17B7 HSD11B1 1/4885MEN1 1683/4885KMT2A 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.